Plasma Fractionation Market Analysis

  • Report ID: 4548
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Plasma Fractionation Market Segmentation:

Application Segment Analysis

The global plasma fractionation market is segmented and analyzed for demand and supply by application into immunology, hematology, critical care, rheumatology, and neurology. Out of these, the neurology segment is anticipated to garner the largest revenue by the end of 2035, backed by increasing cases of neurological disorders such as Alzheimer, and Parkinson’s. According to the Pan America Health Organization, in 2019, neurological diseases were responsible for 533,172 deaths in the region, with men accounting for 213,129 (40%) and women accounting for 320,043 (60%). Also, the application of immunoglobulin is supposed to increase in the forecast period for treating cases of chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis, and inflammatory myopathies, thus expanding the segment share in the forecast period. Also, the rise in old age patients suffering from neurological disease across the globe along with increased research activities for using IVIG for neurology indications is another factor that is considered to bring growth opportunities.

End-user Segment Analysis

The global plasma fractionation market is also segmented and analyzed for demand and supply by end-user in hospitals, clinical research labs, and academic institutes. Out of these, the hospitals segment is attributed generate the highest revenue during the forecast period. The major factor that is attributed to fuel the segment’s growth is the increasing adoption of plasma fractionation products in treating various disorders which includes autoimmune disease, neurological diseases, bleeding, and other disorders, along with the increased patient pool opting for plasma-derived therapies worldwide. Further, the growing number of hospitals in every region of the world and the presence of plasma donation centers in hospitals are also estimated to fuel the segment’s growth. Other growth factors for the segment development include rising investments in the hospital infrastructure, and the expansion of the healthcare sector.

Our in-depth analysis of the global market includes the following segments:

         By Application

  • Immunology
  • Hematology
  • Critical Care
  • Rheumatology
  • Neurology

          By Product

 

  • Immunoglobulins
  •  
  •  
  • Coagulation Factors
  • Albumin

         By End-User

  • Hospitals
  • Clinical Research Lab
  • Academic Institutes

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of plasma fractionation is estimated at USD 39.64 Billion.

The global plasma fractionation market size was more than USD 36.95 Billion in 2025 and is anticipated to grow at a CAGR of over 8.1%, reaching USD 80.51 Billion revenue by 2035.

North America plasma fractionation market will hold over 41.6% share by 2035, fueled by a high number of hemophilic patients and rising prevalence of other chronic diseases.

Key players in the market include CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Octapharma AG, Bio Products Laboratory Ltd., Biotest AG, LFB Group, Japan Blood Products Organization, Intas Pharmaceuticals Ltd.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos